Navigation Links
Topical Spray Helped Men With Premature Ejaculation
Date:4/6/2009

Study found they could delay orgasm six times longer than before

MONDAY, April 6 (HealthDay News) -- A new spray enabled men with premature ejaculation to delay their orgasm six times longer than before, according to a study that included 300 European men.

The men, with clinically diagnosed premature ejaculation, were randomly selected to receive a placebo spray with no active ingredients (100 men) or the PSD502 spray, which contains 7.5 milligrams of lidocaine and 2.5 mg of prilocaine (200 men).

During the three-month study, the men used either the placebo or the PSD502 spray five minutes before intercourse. The men and their partners then used a stopwatch to record the time from vaginal penetration to ejaculation. The men were instructed to abstain from sexual activity or masturbation for 24 hours before each recorded episode of intercourse.

The men who used the PSD502 spray (treatment group) delayed their orgasm from an average of 0.6 minutes to 3.8 minutes, compared to just over 1 minute for those who used the placebo spray. That means the PSD502 spray helped men last 6.3 times longer than normal, compared to 1.7 times longer than normal for those who used the placebo, the study authors said.

The study found that after three months of treatment:

  • 90 percent of the men in the treatment group were able to delay ejaculation for more than 1 minute following vaginal penetration, compared with 54 percent of those in the placebo group.
  • 74 percent of men in the treatment group were able to last 2 minutes before ejaculation, compared with 22 percent of those in the placebo group.
  • 62 percent of men in the treatment group said their orgasms were "good" or "very good" after three months, compared with 20 percent before the start of the study. For men in the placebo group, the figures were 19 percent at the end of the study and 21 percent before the start of the study.
  • More patients and partners in the treatment group reported improvements in perceived control, personal distress, satisfaction with sexual intercourse, and interpersonal problems.

The most common problems noted in the study were loss of erection and a burning sensation in the vagina.

The study findings were published in the April issue of the journal BJU International.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy," lead researcher Professor W. Wallace Dinsmore, of the Royal Victoria Hospital in Belfast, U.K., said in a news release.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation."

More information

The U.S. National Library of Medicine has more about premature ejaculation.



-- Robert Preidt



SOURCE: BJU International, news release, April 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
Breaking Medicine Technology: